Module 446

Jump to: General properties | Gene sets | Enriched clinical annotations | Enriched Go annotations | Visual display
General Properties
Below we list the number of gene sets from which the module was composed was originally composed, and the number of genes and experiments that it contains. Clicking on the number of genes will display a detailed list of all the genes in the module. Clicking on the number of experiments will display a detailed list of all the experiments in the module.
Num gene sets: 2
Num genes: 17 (see 210 additional genes for this module)
Num experiments: 107 (22 induced, 85 repressed)


Jump to: General properties | Gene sets | Enriched clinical annotations | Enriched Go annotations | Visual display
Gene sets
Below we list the gene sets from which the module was originally composed. Clicking on a gene set will display all the genes associated with that gene set. Also listed are all the other modules in which the gene set participates.
coreceptor activity 446 570
cell differentiation 446 570


Jump to: General properties | Gene sets | Enriched clinical annotations | Enriched Go annotations | Visual display
Enriched clinical annotations
For each of the clinical annotations, we tested whether it was enriched in the set of experiments in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) experiments in which they appear. We also show the fraction of experiments with the given annotation that are included in this module ('Hits (%)' column). Rows that correspond to annotations that were enriched in the induced experiments of the module have a red background, while rows corresponding to annotations enriched in the repressed experiments have a green background. For each annotation, we also list the other modules in which it was enriched.
Clinical annotation P-value Hits Hits(%) Modules
CNS cancer or cell line 1.69e-21 38 44.705 1 2 3 5 6 8 11 12 13 15 16 17 18 19 24 28 29 32 33 38 44 47 50 52 53 55 60 62 66 72 83 84 88 91 100 103 105 111 114 118 137 151 152 155 157 159 174 177 183 190 241 257 274 291 299 307 321 322 323 350 381 395 425 443 446 447 460 468 473 474 477 483 497 515 533 563 570
CNS tumor 1.46e-20 36 42.352 1 2 3 5 6 8 11 12 13 15 16 17 18 19 20 24 28 29 32 33 38 39 44 47 50 52 53 55 60 62 66 72 83 88 91 100 103 105 111 114 118 137 151 152 155 157 159 174 177 183 190 241 257 274 291 299 307 321 322 323 350 381 388 395 425 443 446 447 460 468 473 474 477 483 494 497 513 515 533 563 570
CNS 1.54e-20 38 44.705 1 2 3 5 6 8 11 12 13 15 16 17 18 19 20 24 28 29 32 33 38 44 47 50 52 53 55 60 62 66 72 83 84 88 91 100 103 105 111 113 114 118 137 151 152 155 157 159 174 177 183 190 241 257 274 291 299 307 321 322 323 350 381 395 425 443 446 447 460 468 473 474 477 483 494 497 515 533 563 570
Classic Medulloblastoma 2.82e-15 19 22.352 1 2 3 5 6 8 11 12 15 17 18 19 24 32 38 44 47 52 60 66 72 83 88 100 105 111 114 118 137 151 152 155 157 159 190 321 323 443 446 447 460 468 474 494 497 515 570
Chemo vincristine 4.29e-15 21 24.705 1 2 3 5 6 8 11 12 17 18 19 20 24 28 32 38 44 47 50 52 60 62 66 72 83 88 91 100 105 111 114 118 137 151 152 155 157 159 177 190 257 307 321 323 443 446 447 460 468 474 494 497 515 570
AT/RT (CNS and not) 1.42e-14 10 11.764 3 4 8 13 17 28 32 50 62 81 82 83 86 87 91 102 103 105 111 112 113 114 115 149 151 152 155 157 159 176 233 245 250 274 278 299 316 321 386 425 446 447 468 473 483 497 565 570
Medulloblastoma 5.55e-14 21 24.705 1 2 3 5 6 8 11 12 15 17 18 19 20 24 28 29 32 38 44 47 50 52 55 60 62 66 72 83 88 91 100 103 105 111 114 118 137 151 152 155 157 159 174 177 190 257 299 307 321 323 443 446 447 460 468 474 494 497 515 570
Chemo cisplatin 1.41e-13 19 22.352 1 2 3 5 6 8 11 12 17 18 19 20 28 32 38 44 47 50 52 60 62 66 72 83 88 91 100 105 111 114 118 137 151 152 155 157 159 177 190 257 307 321 323 443 446 460 468 474 494 497 515 570
Chemo cytoxan 6.54e-13 18 21.176 1 2 3 5 6 8 11 12 15 17 18 19 28 32 38 44 47 50 52 60 62 66 72 83 88 91 100 105 111 114 118 137 151 152 155 157 159 190 257 307 321 323 443 446 460 468 474 494 497 515 570
Prostate 9.96e-10 22 25.882 5 6 7 11 12 13 15 16 18 19 20 22 23 24 25 28 29 32 38 41 42 43 44 45 52 53 55 60 62 66 68 72 74 77 81 83 84 88 89 91 93 96 100 103 104 106 111 112 113 114 115 116 118 137 144 146 149 150 151 152 157 159 176 181 183 202 203 217 220 242 273 298 299 307 323 342 351 355 363 379 387 405 419 429 446 447 452 494 519 521 524 542 552 564 570
Stage M1 5.47e-09 15 17.647 1 2 3 5 6 8 11 12 17 18 19 28 32 38 47 52 66 72 83 100 105 114 118 137 151 152 155 157 159 190 321 323 443 446 460 474 497 515 570
Prostate cancer 4.98e-08 14 16.470 5 6 7 11 12 13 15 16 18 19 20 22 23 24 25 29 32 38 41 43 44 45 53 55 60 62 66 68 77 81 83 84 88 89 90 93 96 100 104 106 111 112 113 114 115 118 127 137 146 149 151 152 157 159 176 181 202 203 220 222 242 273 298 342 355 363 379 405 419 443 446 447 519 521 524 552 570
Stage M1- brain 5.91e-08 12 14.117 1 2 3 5 6 8 11 12 17 18 19 28 32 38 47 52 60 66 72 83 91 100 105 111 114 118 137 151 152 155 157 159 190 321 323 443 446 447 460 474 497 515 570
Prostate cancer and cell line 1.26e-07 14 16.470 5 6 7 11 12 13 15 16 18 19 20 22 23 24 25 29 32 38 41 44 45 53 55 60 62 66 68 77 81 83 84 88 89 90 93 96 100 104 106 111 112 114 115 118 127 137 146 149 151 152 157 159 176 181 202 203 220 222 242 273 298 342 355 363 379 405 419 443 446 447 519 521 524 552 570
AT/RT CNS 1.38e-07 5 5.882 111 113 157 274 386 446 468 497 565 570
AT/RT non-CNS 1.38e-07 5 5.882 28 32 50 81 83 91 102 103 111 113 114 149 151 155 157 159 245 274 299 386 425 446 447 468 483 497 570
negative margin PC 2.52e-07 11 12.941 5 6 7 12 13 15 16 18 19 20 22 23 24 25 32 38 41 42 43 44 53 55 60 62 68 72 77 81 83 84 88 93 96 104 106 111 114 115 118 146 149 151 152 157 159 181 202 220 242 273 298 299 342 355 363 379 419 446 447 494 519 521 524 570
No cap penet PC 1.78e-06 9 10.588 5 6 7 12 13 16 18 19 20 22 23 24 25 32 38 41 44 53 55 60 62 68 72 81 83 84 88 93 96 104 111 114 115 118 146 149 151 152 157 159 181 202 220 242 273 298 342 355 379 419 446 447 521 524 570
Chemo etoposide 1.91e-06 7 8.235 1 2 3 6 8 11 12 18 19 38 47 52 60 66 72 100 118 137 159 257 321 443 446 474 497 515 570
Dead - Brain tumor 6.28e-06 11 12.941 1 2 3 5 6 8 11 12 13 18 19 28 32 38 47 60 62 66 72 83 91 100 111 114 118 137 151 152 159 167 274 307 321 381 388 438 446 447 477 483 497 515 533 563 570
Cancer tissue 1.16e-05 67 78.823 1 2 3 5 6 7 8 10 11 12 13 19 23 24 27 29 33 36 38 40 41 44 45 46 47 52 55 58 60 63 64 65 66 68 70 72 75 76 78 84 88 89 90 92 93 94 99 100 104 105 107 109 111 112 113 117 118 120 122 127 129 130 131 137 138 140 142 148 153 154 157 164 165 167 168 172 173 174 175 176 181 189 190 194 201 203 204 206 207 209 211 213 214 216 220 222 230 234 235 241 242 247 248 249 250 267 274 290 291 295 297 298 316 324 326 327 329 330 340 341 342 347 357 372 373 374 379 381 382 384 385 387 391 401 404 407 411 416 421 422 426 428 431 435 438 440 446 461 462 464 466 468 469 474 479 483 486 487 497 500 506 512 513 514 515 520 525 533 540 543 549 552 564 570 573
Stage T4 - CNS 1.51e-05 5 5.882 446 497 515
Alive - Brain tumor 9.77e-05 10 11.764 1 2 3 5 6 8 11 12 15 17 18 19 24 28 32 38 44 47 50 52 60 66 72 88 91 100 105 114 118 137 151 152 155 159 174 190 241 257 274 299 321 443 446 460 474 477 483 497 515 533 563 570
Stage T3 - CNS 0.00010 7 8.235 1 2 3 5 8 11 12 15 17 18 19 28 32 38 47 50 52 66 72 83 91 100 105 111 114 118 137 151 152 155 157 159 190 321 323 443 446 460 474 497 515 570


Jump to: General properties | Gene sets | Enriched clinical annotations | Enriched Go annotations | Visual display
Enriched GO annotations
For each GO annotation, we tested whether it was enriched in the set of genes of the module. Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of genes in which they appear. We also show the fraction of genes with the given GO annotation that are included in this module ('Hits (%)' column).
GO annotation P-value Hits Hits(%)
coreceptor activity 1.60e-23 9 52.941
lymphocyte activation 5.63e-19 11 64.705
cell activation 3.91e-15 9 52.941
cell differentiation 4.48e-15 9 52.941
immune response 1.83e-14 13 76.470
response to biotic stimulus 1.30e-10 11 64.705
defense response 1.90e-10 10 58.823
chemokine receptor activity 1.03e-08 4 23.529
MHC protein binding 1.64e-07 3 17.647
organogenesis 2.12e-07 8 47.058
morphogenesis 4.36e-07 8 47.058
chemokine binding 9.79e-07 3 17.647
development 1.12e-06 9 52.941
chemotaxis 1.37e-06 5 29.411
peptide receptor activity 4.31e-06 4 23.529
cellular defense response 5.00e-06 4 23.529
receptor activity 7.52e-06 9 52.941
T-cell activation 9.18e-06 3 17.647
response to pest/pathogen/parasite 9.48e-06 6 35.294
transmembrane receptor protein tyrosine kinase signaling pathway 1.22e-05 4 23.529
signal transducer activity 1.49e-05 11 64.705
inflammatory response 3.09e-05 5 29.411
neurogenesis 5.72e-05 5 29.411


Jump to: General properties | Gene sets | Enriched clinical annotations | Enriched Go annotations | Visual display
Visual display
Below is a visual display of the module. Shown are those arrays in which the module's genes significantly change, and the direction of change (induction/repression) in each array is indicated (middle, labeled 'Module changes'; red/green row). The arrays that correspond to the significant clinical attributes are also shown (top; brown rows). The gene sets that compose the module are also shown (left) along with an indication of the membership of the module genes in these gene sets.
You can also view the images within GeneXPress by loading the module gxp file file.
 
 





 >4x